Navigation Links
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Date:8/19/2007

le insulin, is likely to have greater impact on outcomes and become the preferred means for delivering insulin for Type 2 diabetics.

The first inhalable insulin product, Pfizer's EXUBERA(R), was approved by the European Commission on January 26th 2006 and by the FDA on January 27th 2006. Following the launch of EXUBERA(R) inhaled insulin has become available for diabetics and the way is being paved for next generation products.

About Glucose Clamp Technique

Glucose clamp technique is a technique that maintains a constant blood glucose level in human subjects by perfusion or infusion with glucose; the technique is used in studies to obtain evidence of the effectiveness and bioavailability of preparations of insulin in healthy human volunteers, and patients who suffer from diabetes.

Glucose clamp techniques represent the gold standard for pharmacodynamic and pharmacokinetic studies to describe the time-action profiles of glucose-lowering drugs; the effects of these drugs administered by various routes of administration can be studied individually, and then compared. For example, the effects of inhaled versus subcutaneous insulin.

The European regulatory authority EMEA expressly refers to the glucose clamp technique in an EMEA/ CPMP Note for Guidance.


'/>"/>
SOURCE MicroDose Technologies, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... 2015 NxStage Medical, Inc. (Nasdaq: NXTM ... reported first quarter financial results that exceed the top ... for the first quarter of 2015 increased 10 percent ... for the first quarter of 2014. The Company,s revenue ... to $78.5 million.  The increase was driven by outperformance ...
(Date:5/6/2015)... , May 6, 2015  IGI Laboratories, Inc. (NYSE-MKT: IG), ... pharmaceutical company, will be presenting today at the Deutsche Bank ... on May 6 th and 7 th at ... Jason Grenfell-Gardner , CEO and President and ... will present today, May 6, 2015, at 3:30 p.m. ET.   ...
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
Breaking Medicine Technology:NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 2NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 3NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 4NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 5NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 6NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 7NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 8NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 9NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 10NxStage Reports First Quarter 2015 Financial Results And Exceeds Guidance 11Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... Data presented yesterday showed that USL255, a novel ... less fluctuation in topiramate plasma levels than immediate-release ... These and other findings from the USL255 early ... the 64th annual American Epilepsy Society (AES) meeting ...
... Dec. 6, 2010 The Novartis Pharmaceutical Corporation ... disease control and tumor reduction in extensively pretreated ... become refractory after an autologous stem cell transplant, ... clinical trial presented today(1). In this ...
Cached Medicine Technology:Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 2Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 3Data Suggests Positive Pharmacokinetic Results From Phase I Research of Extended-Release Topiramate 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 2Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 3Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 4Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 5Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 6Novartis Phase II LBH589 data show substantial disease control and tumor reduction in extensively pretreated Hodgkin lymphoma patients 7
(Date:5/6/2015)... Is Colorado’s legal cannabis industry the victim of ... will mark the 18-month milestone of its historic experiment ... Colorado’s legal marijuana industry has been successful and has ... some new challenges. , For example, many marijuana retailers ... the wake of last month’s “420” cannabis celebrations. And ...
(Date:5/6/2015)... 2015 Inversion Studios, a full-service ... and Pilates classes, provides personalized individual instruction and ... with its new Pilates Ring magic circle. , ... leaner, stronger, more centered and graceful, Inversion Studios ... venue to healthy fitness through yoga and Pilates. ...
(Date:5/6/2015)... Texas (PRWEB) May 06, 2015 vcfo, ... finance, HR, IT and operational support to optimize business ... Consulting CFOs, Jack Lynch and Michael Scheaffer. Both Lynch ... finance and leadership experience. , “We are delighted ... Ellen Wood, vcfo CEO. “Leveraging their background in financial ...
(Date:5/6/2015)... 2015 Wolters Kluwer , a ... students, announced today that in a survey of nearly ... of the clinical decision support resource improves the quality ... 2014, UpToDate users in more than 170 countries worldwide ... on average. In Germany alone, 95% of all university ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto ... of China, has successfully demonstrated a handheld real time ... Anitoa’s handheld qPCR is shown to be capable ... including hepatitis B, C, and E. Coli. This qPCR ... sample and over 9 orders of magnitude dynamic range. ...
Breaking Medicine News(10 mins):Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 2Health News:As Colorado Faces Regional Shortages, Cannabis CEO Says Marijuana Will Eventually Be Traded like Any Other Commodity 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3Health News:vcfo Adds Two Senior Executives to Growing Team 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... NAPA, Calif., April 15 Senetek PLC (OTC,Bulletin Board: ... technologies that target the science of healthy aging, announced ... 2007., Revenue for the year ended December 31, ... for the fourth quarter of 2007,were $223,000, compared with ...
... 15 The Joint Center for,Political and Economic ... of health in order to reduce disparities and ... linked to,socioeconomic status," said Ralph B. Everett, the ... determinants, most health,inequities are avoidable," he added., ...
... a new study to evaluate the impact of a ... Presented at the American Association of Cancer Research Annual ... tracking system is key to improving rates of medical ... eliminating racial disparity in treatment. , Women who ...
... many with the autoimmune disease, researchers say , , TUESDAY, April ... the number of attacks in people with multiple sclerosis appears ... The pill was effective in preventing relapses in more than ... years, according to research that was expected to be presented ...
... Council (ACC) supports the rigorous scientific evaluation process,of ... Evaluation of,Risks to Human Reproduction. Following an expert ... NTP Brief on bisphenol A affirms that,there are ... effects of,bisphenol A on human reproduction and development., ...
... their names to ghost-written studies that exaggerated painkiller,s ... Industry documents reveal that pharmaceutical giant Merck & ... Vioxx research published in top medical journals while ... controversial cox-2 painkiller. , The company apparently also ...
Cached Medicine News:Health News:Senetek PLC Reports 2007 Financial Results 2Health News:Senetek PLC Reports 2007 Financial Results 3Health News:Joint Center Sees Social Determinants of Health as Key to Reducing Disparities at Annual Fund-raising Gala 2Health News:Tracking and feedback registry helps reduce disparities in breast cancer care 2Health News:Pill Reduces Relapses in MS Patients 2Health News:Draft National Toxicology Program Report Supports Safety of Bisphenol A 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 2Health News:Key Vioxx Research Was Written by Merck, Documents Allege 3Health News:Key Vioxx Research Was Written by Merck, Documents Allege 4
... Sterile E*Kits® can be a valuable ... care; when the items necessary for a ... facility protocols and continuum of care are ... are packaged in sequence of use, allowing ...
... trays to dry trays to specialty vaginal ... Cardinal Health offers the widest offering in ... components that are proven to be safe ... of surgical site infections. Cardinal Health Scrub ...
The applicator is designed for a smooth delivery of the solution for surgical procedures....
... Panel consists of plasma specimens with reactivity ... antibodies to HTLV I and II. This ... and diagnostic laboratories to evaluate their anti-HTLV ... test systems are included for comparative analysis ...
Medicine Products: